Long-Term Safety and Efficacy of Ivabradine in Patients with Chronic Stable Angina

López-Bescós, Lorenzo; Filipová, Slavomíra; Martos, Ramón

doi:10.1159/000108387

Cited by 63 publications

(70 citation statements)

References 27 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…40 Heart rate was slowed in both treatment groups, with excessive sinus bradycardia and heart rate less than 40 bpm reportedly occurring in 2 patients in the 7.5 mg twice-daily group. 40 There was a mean increase in QT interval, but when corrected with the Bazett formula, the QTc interval numerically decreased. 40 In a pooled analysis of the BEAUTIFUL and SHIFT trials, adverse reactions occurring more commonly than with placebo included symptomatic and asymptomatic bradycardia (4% each), atrial fibrillation (8%), phosphenes (3%), and blurred vision (0.8%).…”

Section: Adverse Reactionsmentioning

confidence: 90%

“…40 There was a mean increase in QT interval, but when corrected with the Bazett formula, the QTc interval numerically decreased. 40 In a pooled analysis of the BEAUTIFUL and SHIFT trials, adverse reactions occurring more commonly than with placebo included symptomatic and asymptomatic bradycardia (4% each), atrial fibrillation (8%), phosphenes (3%), and blurred vision (0.8%). 32 These adverse events were similar to those reported in the largest randomized controlled trial.…”

Section: Adverse Reactionsmentioning

confidence: 96%

“…1 Data from a 1-year safety and efficacy trial suggest that overall ivabradine is well tolerated, with changes in vision, infections, and aggravation of previous cardiac disease reported most commonly. 40 Visual changes, the most commonly reported adverse reaction, were described as phosphene in nature and were generally transient, with 80% of cases resolving while the patient was still under treatment and the other 20% resolving after ivabradine cessation. 40 Serious cardiac events, including angina aggravation, unstable angina, MI, rhythm disturbances, and cardiac failure, were reported by 13 patients in the 5 mg twice-daily group and in 12 patients in the 7.5 mg twice-daily group, with 3 and 2 patients, respectively, experiencing nonfatal MI.…”

Section: Adverse Reactionsmentioning

confidence: 99%

“…26 Ivabradine 2.5 to 10 mg twice daily was used in clinical trials of coronary artery disease and stable chronic angina. 40,[43][44][45][46] There were no pharmacokinetic differences observed in patients 65 years and older or patients 75 years and older. 1 There are no data regarding the use of ivabradine in patients younger than 18 years.…”

Section: Dosingmentioning

confidence: 99%

See 3 more Smart Citations

Ivadradine

2015

View full text Add to dashboard Cite

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The October 2015 monograph topics are sacubitril/valsartan, daclatasvir, sonidegib, alirocumab, and sodium zirconium cyclosilicate. The Safety MUE is on sacubitril/valsartan.

show abstract

Section: Adverse Reactionsmentioning

confidence: 90%

Section: Adverse Reactionsmentioning

confidence: 96%

Section: Adverse Reactionsmentioning

confidence: 99%

Section: Dosingmentioning

confidence: 99%

See 2 more Smart Citations

Ivadradine

2015

View full text Add to dashboard Cite

show abstract

“…Ivabradine substantially reduced the frequency of angina attacks and the consumption of short-acting nitrates compared with placebo, 6 standard antinational therapies such as beta-blocker or calcium channel blocker 7,8 in the shortterm (2 to 3 months) and maintained antianginal efficacy in long-term (1 year) therapy without development of pharmacological tolerance. 9 Ivabradine also showed significant anti-ischaemic efficacy and improvement of exercise capacity, which are important clinically for angina. Ivabradine demonstrated improvements in time to 1-mm ST-segment depression, to angina onset, and to limiting angina in monotherapy 6,7 or in patients receiving betablocker therapy.…”

Section: Symptomatic Treatment In Patients With Stable Angina Pectorismentioning

confidence: 97%

Ivabradine in practice

Pinto

2015

Eur Heart J Suppl

View full text Add to dashboard Cite

Ivabradine is an innovation in the cardiovascular fraternity with specific heart rate-lowering property, which expresses selective action on pacemaker activity in the sinoatrial node of the heart, resulting into important clinical benefits for improvement in coronary perfusion and pump efficiency. Ivabradine demonstrated substantial antianginal and anti-ischemic efficacy, improvement in exercise capacity and in quality of life in monotherapy or in combination with beta-blockers. The analysis of pooled data from ivabradine angina development programme assessing the antianginal efficacy of ivabradine across several different subgroups provided clinical evidence that ivabradine diminishes angina in all types of patients, whatever their age, sex, severity of angina, and revascularization status, history of previous myocardial infarction, peripheral vascular disease, or diabetes. These clinical benefits make ivabradine an important agent for symptomatic treatment of patients with angina pectoris. The important role of ivabradine in the management of patients with chronic heart failure (HF) is well established and supported by its benefits in prevention of morbidity and mortality demonstrated in SHIFT trial. Efficacy and tolerability of ivabradine in patients with HF, including those with different clinical profiles (elderly; severe disease; low blood pressure; comorbidities, including renal dysfunction, diabetes, chronic obstructive pulmonary disease), make ivabradine particularly pertinent for achievement of all targets in the treatment of HF, including improvement of symptoms and well-being, as well as outcomes. The available wealth of evidence supports the important place of ivabradine as an essential therapeutic modality to enhance the management of patients with angina or chronic HF.

show abstract